Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18470003 | 1.00 | CA1 (0.42) | CA1CA2CA4TP53TSHR | |
| SCHEMBL15013813 | 1.00 | CA1 (0.42) | CA1CA2CA4TP53TSHR | |
| SCHEMBL295511 | 1.00 | CA1 (0.42) | CA1CA2CA4TP53TSHR | |
| SCHEMBL15012789 | 1.00 | CA1 (0.42) | CA1CA2CA4TP53TSHR | |
| SCHEMBL23988644 | 1.00 | CA1 (0.42) | CA1CA2CA4TP53TSHR | |
| SCHEMBL1655329 | 1.00 | CA1 (0.42) | CA1CA2CA4TP53TSHR | |
| SCHEMBL23988604 | 1.00 | CA1 (0.42) | CA1CA2CA4TP53TSHR | |
| SCHEMBL10265013 | 1.00 | CA1 (0.42) | CA1CA2CA4TP53TSHR | |
| SCHEMBL20609240 | 1.00 | CA1 (0.42) | CA1CA2CA4TP53TSHR | |
| SCHEMBL15012431 | 1.00 | CA1 (0.42) | CA1CA2CA4TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651713-A1 | PLANT TREATMENT COMPOSITIONS COMPRISING CHITOSAN-COATED EMULSIONS | Universität Münster (DE) | 2025-11-26 | — | — | EP | claimed |
| EP-3347445-B1 | FRAGRANCE MIXTURES | SYMRISE AG (DE) | 2024-10-30 | — | — | EP | claimed |
| WO-2024153800-A1 | PLANT TREATMENT COMPOSITIONS COMPRISING CHITOSAN-COATED EMULSIONS | UNIVERSITÄT MÜNSTER (DE) | 2024-07-25 | — | — | WO | claimed |
| US-20220364016-A1 | PERFUME OIL MIXTURE | SYMRISE AG (DE) | 2022-11-17 | — | — | US | claimed |
| WO-2022217147-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | ROSENFELD MARK J (US) | 2022-10-13 | — | — | WO | claimed |
| EP-2787825-B2 | ANTIMICROBIAL COMPOSITION | UNILEVER GLOBAL IP LTD (GB) | 2021-11-03 | — | — | EP | claimed |
| US-20180251705-A1 | FRAGRANCE MIXTURES | SYMRISE AG (DE) | 2018-09-06 | — | — | US | claimed |
| EP-3347445-A1 | FRAGRANCE MIXTURES | Symrise AG (DE) | 2018-07-18 | — | — | EP | claimed |
| CN-107922882-A | Perfume mixture | 西姆莱斯股份公司 | 2018-04-17 | — | — | CN | claimed |
| WO-2017041834-A1 | FRAGRANCE MIXTURES | SYMRISE AG (DE) | 2017-03-16 | — | — | WO | claimed |
| EP-2787825-B1 | ANTIMICROBIAL COMPOSITION | UNILEVER NV (NL) | 2016-06-08 | — | — | EP | claimed |
| EP-2787825-A1 | ANTIMICROBIAL COMPOSITION | Unilever N.V. (NL) | 2014-10-15 | — | — | EP | claimed |
| WO-2013083595-A1 | ANTIMICROBIAL COMPOSITION | UNILEVER N.V. (NL) | 2013-06-13 | — | — | WO | claimed |
| EP-4651713-A1 | PLANT TREATMENT COMPOSITIONS COMPRISING CHITOSAN-COATED EMULSIONS | Universität Münster (DE) | 2025-11-26 | — | — | EP | disclosed |
| US-12421474-B2 | Perfume oil mixture | SYMRISE AG (DE) | 2025-09-23 | — | — | US | disclosed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20100305326-A1 | Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305326-A1 | Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| US-20090170876-A1 | Novel Topical Formulations of Flucytosine | CAMARGO PHARMACEUTICAL SERVICES, LLC (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090068287-A1 | Novel topical formulations of flucytosine and uses thereof | CAMARGO PHARMACEUTICAL SERVICES LLC | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | CA1 1695/4885CA2 1050/4885CA4 2372/4885 |
| US-20100305326-A1 | Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage | CYFIP2, RPS27A, FRS2 | CA1 2290/4885CA2 3338/4885CA4 2772/4885 |
| US-20180251705-A1 | FRAGRANCE MIXTURES | DHCR24, FAM120A, TRPA1 | CA1 2821/4885CA2 3956/4885CA4 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.